Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy.
Future Sci OA
; 9(7): FSO878, 2023 Aug.
Article
en En
| MEDLINE
| ID: mdl-37485441
Between 2019 and 2021, 72 patients received immunotherapy for a metastatic urothelial carcinoma at our institution. We detected markers of inflammation from a common blood test (neutrophils, lymphocytes, platelets and monocytes). We analyzed the role of these markers in our patients. Patients with a lower ratio of these biomarkers at baseline had a significantly longer time to disease progression. They also has a longer survival and higher chance of disease reduction. Moreover, patients with a specific ratio (NLR) increasing more than 0.5, after the first cycle of therapy, had a worse prognosis. It is necessary to evaluate the role of these markers in a trial with new patients enrolled in a prospective way. In fact, the role of these marker in predicting survival and adverse events could be very important for patients' management.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Future Sci OA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Italia